MRFR Year End Sale
Viral Gastroenteritis Market Research Report- Global Forecast till 2030

Viral Gastroenteritis Market Information: By Type of Virus (Norovirus, Rotavirus), By Diagnosis (Physical Examination, Rapid Stool Test), By Drugs (Antibiotics, Antacids, Laxatives, Antimotility Agents), By Indication (Watery Diarrhea, Vomiting) and By End Use (Hospitals, Clinics, Diagnostic Centers, others) -Forecast till 2030

ID: MRFR/Pharma/3027-HCR | December 2022 | Region: Global | 206 Pages         

Viral Gastroenteritis Market Speak to Analyst Request a Free Sample

Market Synopsis of the Viral Gastroenteritis Market:
The Viral Gastroenteritis Market is anticipated to reach USD 6,4772.93 Million by 2030 at 4.40% CAGR during the forecast period 2022-2030. Viral gastroenteritis, also known as stomach flu, is inflammation of the lining of the stomach, small intestine, and large intestine. There are a number of viruses leading viral gastroenteritis such as norovirus, rotavirus, astrovirus and enteric adenovirus. Norovirus and rotavirus are the most common causes of this disease. This disease is transmitted through direct contact with the patient, and contaminated water or food. The main focus of treating the disease is rehydration by drinking enough water or fluids.


The market for viral gastroenteritis is driven by an increasing prevalence of gastrointestinal diseases, availability of cost effective treatment and extensive research and development activities in internal medicine Furthermore, there is an increasing demand for the new drugs for the treatment of the disease.


Bacterial resistance to commonly used antibiotics such as penicillin and amoxicillin may be the leading restrain for the growth of the market. Fierce competition among key market players acts as a barrier for the new entrant in the market.


According to the World Health Organization (WHO), diarrheal diseases are a major cause of hospitalizations and child deaths globally.


FIGURE 1: Global Viral Gastroenteritis Market by Region, 2016 (%) Viral Gastroenteritis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Key Players in the Global Viral Gastroenteritis Market 
Valeant Pharmaceuticals International Inc. (U.S.), Janssen Global Services, LLC U.S.), Takeda Pharmaceutical (Japan), Bayer AG (Germany), Sanofi (France), Allergan (Ireland), GlaxoSmithKline (U.S.), Abbott (U.S.),  and AstraZeneca (U.K).
Segments   
                                                                                                                                       
The global viral gastroenteritis market is segmented on the basis of type of virus, diagnosis, drugs, indication, and end user.


On the basis of type of virus, market is segmented into norovirus, rotavirus, astrovirus, and enteric adenovirus.


On the basis of diagnosis, the market is segmented into physical examination and rapid stool test.


On the basis of drugs, the market is segmented into Antibiotics, antacids, laxatives, antimotility agents and others. Other drugs are antiemetics and chemotherapy drugs.


On the basis of indication, the market is segmented into watery diarrhea, vomiting, abdominal cramps and pain and others.


On the basis of end user, the market is segmented into hospitals, clinics, pharmaceutical companies, diagnostic centers, ambulatory care centers and others.


Research Methodology Viral Gastroenteritis Market-

Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 


 


Regional Analysis of the Global Viral Gastroenteritis Market               
America is the largest market for viral gastroenteritis owing to rising prevalence of viral gastroenteritis in the U.S., especially among the pediatric population. According to the Center For Disease Control And Prevention (CDC), each year on average in the United States, there are 19 to 21 million cases of acute gastroenteritis.


Europe is the second largest market for viral gastroenteritis. According to an article published in the journal of Clinical Virology, in Europe, acute infectious gastroenteritis is one of the major causes for substantial morbidity and economic loss.


In Asia Pacific, the common cause of severe gastroenteritis in children less than 5 years of age, is rotavirus. The market in Asia Pacific is driven by an increasing demand for rapid diagnostic tests for gastrointestinal diseases and increasing awareness about available treatment options for viral gastroenteritis. Also, growing investments in the field of life science research and demand for advanced therapies for the treatment of gastrointestinal diseases in developing nations such as China and India will propel the growth of the Asia Pacific market.


The Middle East & Africa also show a steady rise in the market owing to increasing number of cases of diarrhea due to viral infection.


 Intended Audience



  • Gastrointestinal Drug Manufacturers

  • Gastrointestinal Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors



Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Viral gastroenteritis market is projected to grow at a 4.40% CAGR between 2022- 2030.

The Americas is expected to dominate the viral gastroenteritis market.

Availability of cost effective treatment and rising prevalence of gastrointestinal diseases are the key factors driving the viral gastroenteritis market growth.

Fierce competition among industry players and bacterial resistance to antibiotics may limit the viral gastroenteritis market growth.

Leading players profiled in the viral gastroenteritis market include AstraZeneca (U.K), Abbott (U.S.), GlaxoSmithKline (U.S.), Allergan (Ireland), Sanofi (France), Bayer AG (Germany), Takeda Pharmaceutical (Japan), Janssen Global Services, LLC U.S.), and Valeant Pharmaceuticals International Inc. (U.S.).